Curriculum Vitae

Kottil W. Rammohan, MD

I. PERSONAL

Address

Office: University of Miami School of Medicine
Department of Neurology, MS Research Center
Clinical Research Building
1120 NW 14th Street, Suite 1322
Miami, Florida 33136

Phone

Office: 305-243-4655
Fax: 305-243-8108
Admin: 305-243-4015

Current Rank:

Emeritus Professor of Neurology The Ohio State University, Columbus, Ohio	February 2010 to Present
Professor – Clinical Neurology University of Miami, Miami, Florida	August 2010 to Present

Department:

Neurology

Citizenship:

USA

II. HIGHER EDUCATION

a. Pre-University Diploma (Pre Med)
Loyola College, Chennai, India June 1961- June 1962

b. Medical Education (MB&BS - Bachelor of Medicine and Bachelor of Surgery)
Madras Medical College
Chennai, India July 1962 - December 1967

The degree was conferred in the Convocation of March 1969

Award and Honors during Medical School

Awards are determined on the basis of performance in examinations specifically administered to determine competence and excellence in a specific subject. The class of 1969 comprised of 282 students.

Col. Van Geyzel Prize	Organic Chemistry 1963-1964	
Dr. Rajasekhara Reddy Prize	Anatomy 1963-1964	
Dr, G. *Rama Rao Gold Medal*	Anatomy 1964-1965	
Dr. M. *Govinda Menon Gold Medal*	Anatomy 1964-1965	
Dr. Samuel Jesudoss Prize	Pharmacology 1965-1966	
Bannerman Prize	Microbiology/Immunology 1966-1967	
Rukhmani Memorial Prize	Ophthalmology	1966-1967
George Smith Prize	Pathology	1966-1967
Nutrition Prize Essay and elocution on Nutrition	1966-1967	
First Certificate of Honor	Pathology	1966-1967
The Chipperfield Gold Medal	Clinical Medicine	1967 - 1968
Allan Evan Grant Prize	Medicine	1967 - 1968
Sibthorpe Prize I	*Surgery*	*1967 - 1968*

Maitland Memorial Prize	Medicine	1967 - 1968
Dr. KM.Rai Gold Medal	Radiology	1967 - 1968
Dr. J.A.S. Masilamani memorial Gold Medal Class of 1967	Valedictorian	1969

The Johnston Gold Medal *1969*
Best-outgoing student of the year - class of 1967
Best-outgoing student with best overall performance.This prize is not awarded every year. Performance of the student is assessed fromentry to completion of medical school.

Awards and Honors - University of Madras

The University of Madras awards medical degrees (MB&BS) to seven different medical school. These are, Madras Medical College, Stanley Medical College, Kilpauk Medical College, Madurai Medical College, Tanjore Medical College, Vellore Medical College, and the Post-graduate Institute at Pondicherry. Over 600 medical students participate in these examinations, and awards of merit are determined from the overall performance. The following awards were received.

The Rajah of Panagal Medal 1969
Awarded to the best out-going medical student of the year
from the University of Madras (Seven Medical Schools)
Dr. A. *Lakshmanaswami Mudaliar Gold Medal* : 1969
Awarded for excellence in Obstetrics and Gynecology
from the University of Madras

Dr. A. C. *Asirvada Nadar Memorial Prize*
Awarded for overall academic excellence
from the University of Madras
Class of 1967. Awarded 1967

TRAINING IN THE UNITED STATES

Straight Medicine Internship Cook County Hospital Chicago, Illinois	June 23rd 1970 to July 1st 1971
Internal Medicine Residency Cook County Hospital Chicago, Illinois	July 1st 1971 to December 31st 1971
Internal Medicine Residency The Ohio State University, Columbus, Ohio	January 3rd 1972 to June 30th 1973

Neurology Residency
The Ohio State University
Columbus, Ohio July 1st 1973 to June 30th 1976

Awards and Honors· Residency
Award of Merit, Internal Medicine,
Ohio State University 1973
Outstanding resident of the year, for outstanding performance in Clinical Medicine, from the Department of Medicine at Ohio State University

Fellowship in Neurovirology and Neuroimmunology
Senior Clinical Associate
Neuroimmunology Branch, National Institutes of Health
Bethesda, Maryland August 1976 to December 1981

BOARD CERTIFICATION

American Board of Internal Medicine - Certified June 20th 1973

American Board of Psychiatry and Neurology with special competence in Neurology
Certified April 1978

American Society of Neurorehabilitation
Certified 3/19/1993

Licensure

Florida Awarded on 5/4/2010	Active	**Licence # ME107082**
Ohio Awarded March 7th 1969	Active	**Licence # 35-036498**
Maryland Awarded 8/18/1977	Inactive	
Illinois Awarded 2/7/1973	Inactive	

III. EXPERIENCE

Academic Appointments:

Assistant Professor
Department of Neurology
The Ohio State University January 1982 to July 1987

Associate Professor
Department of Neurology
The Ohio State University July 1987 to July 2003

Professor
Department of Neurology
The Ohio State University July 2003 to January 31st 2010

Emeritus Professor
Department of Neurology
The Ohio State University 2/1/2010 to Present

Professor – Clinical Neurology
Department of Neurology
University of Miami Miller School of Medicine

Non-Academic Appointments & Titles:

Director
Multiple Sclerosis Center
University of Miami August 2nd 2010 to Present

Director, Clinical and Experimental Neuroimmunology
The Ohio State University,
Department of Neurology January 1982 to January 2010

Director, Multiple Sclerosis Center
The Ohio State University
Department of Neurology January 1982 to January 2010

Director, Special Functions laboratory
University Reference Laboratory
The Ohio State University July 1990 to January 2010

Vice Chair
Department of Neurology
The Ohio State University July 1991 to June 2000

Hospital Appointments:

The Ohio State University Hospitals 1982 to 2010

The Ohio State University Hospitals include, University Hospital, Ohio State University Hospital East, and The James Cancer Center.

Military Service:

None

IV. PUBLICATIONS

Van Pottelsberghe C, Rammohan KW, McFarland HF, Dubois-Dalcq M. Selective neuronal, dendritic, and postsynaptic localization of viral antigen in measles-infected mice. Lab Invest. 1979 Jan;40(1):99-108.

Rammohan KW, McFarlin DE, McFarland HF. Chronic measles encephalitis in mice. J Infect Dis. 1980 Oct;142(4):608-13.

Gheuens J, McFarlin DE, Rammohan KW, Bellini WJ. Idiotypes and biological activity of murine monoclonal antibodies against the hemagglutinin of measles virus. Infect Immun. 1981 Oct;34(1):200-7.

Rammohan KW, McFarland HF, McFarlin DE. Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature. 1981 Apr 16;290(5807):588-9.

Rammohan KW, McFarland HF, McFarlin DE. Subacute sclerosing panencephalitis after passive immunization and natural measles infection: Role of antibody in persistence of measles virus. Neurology. 1982 Apr;32(4):390-4.

Rammohan KW, McFarland HF, Bellini WJ, Gheuens J, McFarlin DE. Antibody-mediated modification of encephalitis induced by hamster neurotropic measles virus. J Infect Dis. 1983 Mar;147(3):546-50.

Rammohan KW. Oligoclonal bands in unconcentrated CSF. silver stain for agarose gels. Neurochem Pathol. 1985 Spring;3(1):15-25.

Sheshberadaran H, Norrby E, Rammohan KW. Monoclonal antibodies against five structural components of measles virus. II. characterization of five cell lines persistently infected with measles virus.
Arch Virol. 85;83(3-4):251-68.

Bellini W, Englund G, Rammohan K, McFarlin DE. Evaluation of the structural proteins of the hamster neurotropic strain of measles virus with monoclonal antibodies. J Neuroimmunol. 1986 Apr;11(2):149-63.

Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6;314(6):329-34.

Sellers KL, Chioran GM, Dain SJ, Benes SC, Lubow M, Rammohan K, et al. Red-green mixture thresholds in congenital and acquired color defects. Vision Res. 1986;26(7):1083-97.

Huber SJ, Paulson GW, Shuttleworth EC, Chakeres D, Clapp LE, Pakalnis A, et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol. 1987 Jul;44(7):732-6.

Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan KW. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987 Aug;37(8):1291-4.

Huber SJ, Paulson GW, Chakeres D, Pakalnis A, Brogan M, Phillips BL, Myers MA, Rammohan KW. Magnetic resonance imaging and clinical correlations in multiple sclerosis. J Neurol Sci. 1988 Aug;86(1):1-12.

Kao L, Krstenansky J, Mendell J, Rammohan KW, Gruenstein E. Immunological identification of a high molecular weight protein as a candidate for the product of the duchenne muscular dystrophy gene. Proc Natl Acad Sci USA. 1988 Jun;85(12):4491-5.

Kassicieh D, Drake ME,Jr, Shuttleworth EC, Rammohan KW. Conduction aphasia following metrizamide myelography. J Am Osteopath Assoc. 1988 Mar;88(3):384-6.

Farooqui AA, Rammohan KW, Horrocks LA. Isolation, characterization, and regulation of diacylglycerol lipases from the bovine brain. Ann N Y Acad Sci. 1989;559:25-36.

Kissel JT, Riethman JL, Omerza J, Rammohan KW, Mendell JR. Peripheral nerve vasculitis: Immune characterization of the vascular lesions. Ann Neurol. 1989 Mar;25(3):291-7.

Dain SJ, Rammohan KW, Benes SC, King-Smith PE. Chromatic, spatial, and temporal losses of sensitivity in multiple sclerosis. Invest Ophthalmol Vis Sci.1990 Mar 1;31(3):548-58.

Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated duchenne dystrophy. CIDD study group.
Neurology. 1991 May;41(5):661-6.

Kissel JT, Burrow KL, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated duchenne muscular dystrophy. CIDD study group. Neurology. 1991 May;41(5):667-72.

Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol. 1991 Jan;48(1):26-30.

Kissel JT, Rammohan KW. Pathogenesis and therapy of nervous system vasculitis. Clin Neuropharmacol. 1991 Feb;14(1):28-48.

Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis.
J Neuropsychiatry Clin Neurosci. 1992 pring;4(2):152-8.

Lynn J, Rammohan KW, Bornstein RA, Kissel JT. Central nervous system involvement in the eosinophilia-myalgia syndrome.
Arch Neurol. 1992 Oct;49(10):1082-5.

Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT,3rd, et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy.
Neurology. 1993 Mar;43(3 Pt 1):532-6.

Tan E, Lynn DJ, Amato AA, Kissel JT, Rammohan KW, Sahenk Z, et al. Immunosuppressive treatment of motor neuron syndromes. attempts to distinguish a treatable disorder. Arch Neurol. 1994 Feb;51(2):194-200.

Basso MR, Beason-Hazen S, Lynn J, Rammohan K, Bornstein RA. Screening for cognitive dysfunction in multiple sclerosis.
Arch Neurol. 1996 Oct;53(10):980-4.

Ball R, Halsey N, Braun MM, Moulton LH, Gale AD, Rammohan K, et al. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse event reporting system. J Clin Epidemiol. 2002 Aug;55(8):819-24.

Burks JS, Arnason BG, Coyle PK, Ford CC, Noronha A, Rammohan KW. Issues and practices in multiple sclerosis. Neurorehabil Neural Repair. 2002 Dec;16(4):307-20.

Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C, Rammohan K, et al. Optimizing immunomodulatory therapy for MS patients: An integrated management model. J Neurol Sci. 2002 Sep 15;201(1-2):89-90.

Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study.
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-83.

Rammohan KW. Axonal injury in multiple sclerosis. Curr Neurol Neurosci Rep. 2003 May;3(3):231-7.

Zhou Q, Rammohan K, Lin S, Robinson N, Li O, Liu X, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15041-6.

Rammohan KW, Lynn DJ. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study.
Neurology. 2005 Dec 27;65(12):1995,7;

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: The EVIDENCE study.
Arch Neurol. 2005 May;62(5):785-92.

Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Neurology. 2006 Mar 14;66(5):678-84.

Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 tesla. AJNR Am J Neuroradiol. 2007 Feb;28(2):262-6.

Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH, et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet. 2007 Apr 6;3(4):e49.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008 Oct 7;71(15):1134-41.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, et al.
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun;30(6):1102-12.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): A multicentre, randomised, parallel, open-label trial.
Lancet Neurol. 2008 Oct;7(10):903-14.

Minagara A, Murray TJ, PROOF Study Investigators. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: Results from PROOF. Curr Med Res Opin. 2008 Apr;24(4):1049-55.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503-11.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct;8(10):889-97.

Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study. Neurology. 2009 Nov 3;73(18):1493-500.

Rammohan KW. Cerebrospinal fluid in multiple sclerosis. Ann Indian Acad Neurol. 2009 Oct;12(4):246-53.

Rammohan KW. Multiple sclerosis: As we see it today and glimpses of tomorrow. Ann Indian Acad Neurol. 2009 Oct;12(4):204-5. author reply 1995-7.

Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology. 2010 Jan 5;74 Suppl 1:S47-53.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26. Oct;66(4):460-71

Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P. Imaging cortical lesions in multiple sclerosis using ultra high-field magnetic resonance imaging. Arch Neurol. 2010; 67(7): 812-818.

Patent - US, Canadian and European:

http://www.wipo.int/pctdb/en/wo.jsp?wo=2005054810

Patents pending.

Pub. No.: **WO/2005/054810** **International Application No.:** **PCT/US2004/039391**

Publication Date: **16.06.2005** **International Filing Date:** **22.11.2004**

IPC: ***C07H 21/02*** (2006.01), ***C07H 21/04*** (2006.01), ***C12Q 1/68*** (2006.01), ***G01N 33/53*** (2006.01)

Applicants: **THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION** [US/US]; 1960 Kenny Road, Columbus, OH 43201-1063 (US) *(All Except US)*.
LIU, Yang [US/US]; (US) *(US Only)*.
ZHOU, Qunmin [CN/US]; (US) *(US Only)*.
ZHENG, Pan [US/US]; (US) *(US Only)*.
RAMMOHAN, Kottil [US/US]; (US) *(US Only)*.
LIN, Shili [US/US]; (US) *(US Only)*.

Inventors: **LIU, Yang**; (US).
ZHOU, Qunmin; (US).
ZHENG, Pan; (US).
RAMMOHAN, Kottil; (US).
LIN, Shili; (US).

Agent: **MYERS-PAYNE, Sean, C.**; Calfee, Halter & Griswold LLP, 1100 Fifth Third Center, 21 East State Street, Columbus, OH 43215 (US) .

Priority Data: 60/525,502 26.11.2003 US

Title: POLYMORPHIC CD24 GENOTYPES THAT ARE PREDICTIVE OF MULTIPLE SCLEROSIS RISK AND PROGRESSION

Abstract: Methods for predicting the likelihood that an individual will develop multiple sclerosis, or of predicting a rate of multiple sclerosis progression, comprising testing for polymorphisms in CD24, includind 226 C/T, 1110 A/G, and 1580 --/TG.

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

MR, NE, SN, TD, TG).

V. PROFESSIONAL

GRANTS

GRT962618	Effect of early glatiramer acetate treatment in delaying the conversion to clinically definite multiple sclerosis, of patients presenting with a clinically isolated syndrome.	Teva Neuroscience Inc	RAMMOHAN, KOTTIL W;	$37,874.00	01/05/2004 - 01/31/2010
GRT962447	Open-label extension study to evaluate the safety, tolerability, and activity of oral fampridine-SR in subjects with multiple sclerosis.	Acorda Therapeutics	RAMMOHAN, KOTTIL W;	$114,323.65	01/30/2004 - 12/31/2010
GRT962318	Rammohan - 25% TDC.	Ohio State University Residual Funds	RAMMOHAN, KOTTIL W; LYNN, DEBORAH J	$511,780.93	11/01/2003 - 11/17/2009
GRT869389	Controlled high risk multiple sclerosis prevention study in ongoing neurological surveillance.	Biogen IDEC Inc	RAMMOHAN, KOTTIL W;	$27,540.00	01/04/2001 - 12/31/2009
GRT00016359	Rammohan -- 26% TDC	Ohio State University Residual Funds	RAMMOHAN, KOTTIL W; LYNN, DEBORAH J	$22,961.31	11/01/2008 - 11/17/2009
GRT00014007	A phase IIIb, double-blind, placebo-controlled, multicenter, parallel group, extension trial to evaluate the safety	Serono Inc	RAMMOHAN, KOTTIL W;	$14,908.64	05/05/2008 - 10/30/2010

	and tolerability of oral Cladribine in subjects with relapsing-remitting Multiple Sclerosis who have completed trial 25643				
GRT00011374	Neurology operational fund	Clinical Trials Management	RAMMOHAN, KOTTIL W	$458,900.41	01/18/2008 - 01/17/2010
GRT00010519	A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon beta-1a (rebif) in patients with RRMS who have relapsed on therapy	Genzyme Corp	RAMMOHAN, KOTTIL W;	$13,270.00	09/13/2007 - 12/21/2010
GRT00010517	Open-label extension study to evaluate the safety, tolerability and activity of oral Fampridine-SR in patients with multiple sclerosis who participated in the MS-F204 trial	Acorda Therapeutics	RAMMOHAN, KOTTIL W	$18,789.15	09/27/2007 - 10/31/2009
GRT00010035	A randomized, multicenter, placebo-controlled and active reference (Glatiramer Acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis	Biogen IDEC Inc	RAMMOHAN, KOTTIL W; RACKE, MICHAEL; LYNN, DEBORAH J	$9,000.00	08/01/2007 - 12/31/2010
GRT00009840	International, multicenter, phase IIIb study of	Bayer HealthCare Pharmaceuticals	RACKE, MICHAEL;	$11,525.00	07/18/2007 - 12/31/2009

	subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250ug or 500ug or open-label Betaseron/Betaferon 250ug and (Phase B) open	Inc			
GRT00008920	Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with RRMS to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks	UCB Pharma, Inc	RAMMOHAN, KOTTIL W; RACKE, MICHAEL; LYNN, DEBORAH J	$24,904.20	03/01/2007 - 05/31/2010
GRT00007584	24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS	Novartis Pharmaceuticals Corp	RAMMOHAN, KOTTIL W;	$258,133.70	06/29/2006 - 09/30/2011
GRT00006509	Study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting multiple sclerosis	Teva Neuroscience Inc	RAMMOHAN, KOTTIL W;	$173,734.24	08/15/2006 - 09/30/2009

GRT00004381	MS-F203 extension: Open label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in subjects with multiple sclerosis who participated in the MS-F203 trial	Acorda Therapeutics	RAMMOHAN, KOTTIL W; LYNN, DEBORAH J	$34,682.00	01/30/2006 - 12/31/2010
GRT00004329	Study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS)	Serono Inc	RAMMOHAN, KOTTIL W; LYNN, DEBORAH J	$42,542.50	07/10/2006 - 01/30/2010
GRT00000027	Combination therapy using mycophenylate mofetil (CellCept(R)) and human interferon beta 1a (Rebif (R)) in early treatment of multiple sclerosis	Serono/Pfizer	RAMMOHAN, KOTTIL W; LYNN, DEBORAH J	$150,000.00	10/01/2006 - 09/30/2010

ABSTRACTS OF SCIENTIFIC PRESENTATIONS

Rammohan KW, Pottelsberg C, Mcfarland HF, Dubois-Dalcq M. Selective neuronal, dendritic and post synaptic localization of viral antigen in measles infected mice. VIII International Congress of Neuropathology, Washington DC. 1978.

Rammohan KW, McFarlin DE, McFarland HF. Chronic murine measles encephalitisa strain dependent phenomenon. Abstract# 4923, pg.1159, Proceedings of the 63rd annual meeting of the Federation of American Society of Experimental Biology. Dallas, Texas, 1979.

Rammohan KW, Gheuens J, Bellini WJ, McFarland HF, McFarlin DE. Diversity in the in vivo effects of monoclonal antibodies to the measles virus hemaglutinin. Abstract #4737, pg. 1065, Proceedings of the 65th Annual Meeting of The Federation of American Society of Experimental Biology. Atlanta, Georgia 1981.

Gheuens J, McFarlin DE, Bellini WJ, Rammohan KW. Monoclonal antibodies specific for measles hemaglutinin: idiotypes and biological activity. Abstract #4342, pg 996, Proceedings of the 65th annual meeting of the Federation of American Societies of Experimental Biology. Atlanta, Georgia 1981.

Rammohan KW, McFarland HF, McFarlin DE. Subacute murine measles encephalitis: Role of antibody in viral persistence in vivo. Abstract #4. pg. 126. 33rd Annual Meeting of the American Academy of Neurology. Toronto, Canada. 1981.
Rentier B, Rammohan, KW, Bellini WJ, McFarlin DE. Immunocytochemical study of measles infected neurons with monoclonal antibodies to virus hemaglutinin. Vth International Congress of Virology. Abstract #8-21 :122. 1981

Trotter JL, Gebel HM, Garvey WP, Ferguson TB, Rammohan KW, Rodney GE. Induced decrease in percentage of T-g cells and suppression activity in the peripheral blood of patients with multiple sclerosis. Vth International Congress of Virology. Abstract #98. 1981.

Rammohan KW. Role of antibody in viral persistence in subacute murine measles encephalitis. Seminar on infection of differentiated cells with RNA viruses. 82nd Annual Meeting of the American Society of Microbiology. Session 227, 1982.
Rammohan KW, McFarlin DE, McFarland HF, Bellini WJ. Antigenic drift in measles virus hemaglutinin (HA) identified by monoclonal anti-HA antibodies. 66th Annual Meeting of the American Societies of Experimental Biology. Abstract #1744. 1982.

Rammohan KW. Agarose gel electrophoresis and agarose isoelectric focusing of unconcentrated cerebrospinal fluid - a sensitive silver stain for detection of the oligoclonal bands. Annual Meeting of the American Academy of Neurology. SanDiego, California. 1983.

King-Smith PE, Dain SJ, Chioran GM, Sellers KO, Lubow ML, Benes SE, Rammohan KW. Black-white thresholds in acquired color defects. Annual Meeting of

the Association of Research in Vision and Ophthalmology. Supplement to Investigations in Ophthalmology and Visual Sciences. 25:146, 1984.

Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. Neurology 1985; 35 (SuppI1):204
Kissel JT, Rammohan KW, Mendell JR. Absence of complement membrane attack complex in nerves from patients with polyneuropathy and a monoclonal anti-MAG IgM gammopathy. Neurology 1986; 36 (Suppl 1):79

Rammohan KW, Bratton J. Detection of oligoclonal IgG in CSF using immunoblot analysis of isoelectric focusing in agarose. Neurology 1986;36 (suppl 1):315
Kissel JT, Mendell JR, Rammohan KW. Complement membrane attack complex in dermatomyositis. Proceedings of the International congress of Neuromuscular Diseases. Muscle Nerve 1986; 9 (suppl):35

Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres OW, Rammohan KW. Central Nervous system demyelination in patients with inflammatory demyelinating polyneuropathy. Neurology 1986; 36 (suppl 1):255

Rammohan KW, Kissel JT, Paltan J, Andreyejewska W, Chakeres 0, Boesel C. Pathological correlates of lesions by **MRI** in multiple sclerosis. Neurology 1987; 37 (suppl 1):307

Reithman JL, Kissel JT, Rammohan KW, Omerza J, Sahenk Z, Mendell JR. Peripheral nerve vasculitis: immune characterization of vascular lesions. Ann Neurology 1987;22:118

Rammohan KW, Wolinsky J, Omerza J. Gales T. Kissel JT, Mendell JR. Mumps virus in IBM: studies implicating cross reactivity accounting for antigen localization. Neurology 1988; (suppI1):151

Rammohan KW, Calland J, Carney L. OligoclonallgG in tears of patients with multiple sclerosis. Neurology 1988; 38 (suppl 1):251

Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement mediated microvasculopathy to the clinical and histological duration of disease in dermatomyositis. Neurology 1989;39 (suppl 1):338

Chakeres DW, Huber SJ, Bornstein RA, Rammohan KW. Magnetic resonance imaging features of dementia in multiple sclerosis. Neurology 1990; 40 (suppl 1):305
Huber SJ, Bornstein RA, Rammohan KW. A controlled neuropsychological comparison of relapsing-remitting and chronic progressive multiple sclerosis. Neurology 1990; 40 (suppl 1):306

Rammohan KW, Huber SJ, Bornstein RA. Relationship of motor symptoms, intellectual impairment, and personality features in multiple sclerosis. Neurology 1990; 40 (suppl 1):306

Bornstein RA, Huber SJ, Rammohan KW. Callosum atrophy and interhemispheric integration impairment in multiple sclerosis. Neurology 1990; 40 (suppl 1):306.
Burrow KL, Coovert D, Klein CJ, Bulman DE, Rammohan KW, Burghes AHM, Mendell JR. Dystrophin analysis following prednisone treatment of Duchenne muscular dystrophy.Neurology 1990; 40 (suppl 1):206

Kissel JT, Burrow K, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisone treated duchenne muscular dystrophy. Neurology 1990; 40 (suppI1):412

Mendell JR, Iannaccone ST, burrow KL, Fishbeck KH, Rammohan KW, Coovert 0, Bulman D, Bove K, Jacobs IW, Michaels J, Miller G, Burghes AHM. Oystrophin analysis in congenital muscular dystrophy. Annals of Neurology 1990;28 (2): 270
Kissel JT, Rammohan KW, Halterman R, Lynn DJ, Mendell JR. Circulating complement membrane attack complex in dermatomyositis.
Neurology 1991 ;41 (suppl 1):419

Tan E, Rammohan KW, Kissel JT, Sahenk Z, Mendell JR. Antiganglioside antibodies: control population establishes specificity for recognition of motor neuron variants. Annals of Neurology 1991 ;30(2):260

Lynn OJ, Kissel JT, Rammohan KW. Cerebrospinal fluid (CSF) terminal complement complex in multiple sclerosis. Neurology 1992;42 (suppl 3):248
Kissel JT, Lynn OJ, Rammohan KW, Griggs RC, Moxley RT, Brook MH, Cwik V, Mendell JR. Mononuclear cell analysis of muscle biopsies in azathioprine treated Ouchenne dystrophy. Neurology 1992;42 (suppl 3):227

Coulson-Burghes S, Rammohan KW. Experimental Axonal ion channel encephalitis. Annals of Neurology. 1999. 46 (No 3): Abstract 38. Page 456.
Jacobs LO, Beck RW, Brownscheidle C, et al. A profile of patients at high risk forthe development of clinically definite MS (COMS). The first report of the CHAMPS study, AAN 1999

Rammohan KW, Rosenberg JH, Pollak CP, Lynn OJ, Blumenfeld A, Nagaraja HN. Modafinil - Efficacy and safety for the treatment of fatigue in patients with multiple sclerosis. Neurology 2000; 54:A24

Coulson-Burghes S, Gonzales LM, Rammohan KW, Inflammatory infiltrates in Experimental axonal ion-channel encephalitis. Neurology. 2000; 54: A125
Cohen JA, et al and the IMPACT Study Group. One-year change in the multiple sclerosis functional composite and expanded disability status scale in the phase 3 trial of intereron beta-1a in secondary progressive multiple sclerosis.

Neurology. 2000.54(supple 3): A215

Simon JH, Beck J, Jacobs LO, et al. MRI results of a phase III trial of interferon beta-1a treatment in patients at high risk of developing multiple sclerosis. Neurology 2000;54(12):2351. Abstract.

Jacobs LO, Beck R, Simon JH, et al. Results of a phase III trial of interferon beta-1a treatment in patients at high risk of developing multiple sclerosis. Neurology 2000;54(12):2351. Abstract.

Beck R, Galetta S. The effect of interferon beta-1a (AVONEX®) treatment of acute optic neuritis and other first acute clinical demyelinating events on the rate of development of clinically definite multiple sclerosis: results of a randomized, placebo-controlled trial. Oral presentation at the American Academy of Ophthalmology, 2000.

Cohen JA, et al and the IMPACT Study Group. Results of IMPACT, a phase 3 trial of interferon ~ 1a in secondary progressive multiple sclerosis. Neurology2001. 56: Abstract S20.003.A148.

Kinkel R, CHAMPS Investigator Group. The effects of interferon beta-1a (AVONEX®) in high-risk patients: CHAMPS clinical and MRI subgroup analyses.
Mult Sclerosis.2001 ;7(suppI1):S10. Abstract.

Balcer LJ, Baier ML, Kooijmans M, et al. Contrast letter acuity as a candidate visual outcome measure for the MS Functional Composite. Mult Scler 2001 ;7(suppI1):S104. Abstract.

Miller OM, Cohen J, Tsao E, et al. Health-related quality of life in secondary progressive MS patients: Results from the IMPACT study. Mult Scler 2001 ;7(suppl 1):S15. Abstract.
Cohen JA, Baier ML, Cutter GR, et al. Predictive validity of the MS Functional Composite in progressive M8. Mult Scler 2001 ;7(suppl 1):S15. Abstract.

Simon JH, CHAMPS Investigator Group. MRI Predictors of Clinically Definite MS Based on Analyses of Placebo Patients from the CHAMPS Trial. Neurology 2002. 58 (suppl 3) S67.001.

Kinkel RP, CHAMPS Investigator Group. The effect of Avonex in patients with a single demyelinating event and MRI evidence of high lesion burden and active inflammation. Submitted to ENS 2002.

Miller OM, Cohen JA, Tsao EC, et al. Assessing the effects of IFNO-1a on Health Related Quality of Life in secondary-progressive MS patients: results from the IMPACT study. Neurology. 2002 58 (suppI3). P06.075. A456.

Heidenreich F, Goodman AD, Simon JH, et al. Benefit of Interferon beta-1a on MSFC Progression in IMPACT: Analysis of Subgroups. Accepted at ENS 2002.

Rammohan KW, Kangarlu A, Bourekas E, Chakeres D. Ultra high field strength MR imaging of white matter at 8Tesla in multiple sclerosis. Neurology.2002. 58: S26.005.

Sharief MK, and the EVIDENCE study group. Evidence of dose response: effects of two interferon beta-1 a products on relapse related parameters in multiple sclerosis. 2002. Neurology 58: S13.005. A86

Panitch H, Coyle P, Francis G, Goodin 0, O'Connor P, Weinschenker B, and the EVIDENCE study group. The evidence of interferon dose response: European-North American comparative efficacy (EVIDENCE) study: 48 week data. 2002. Neurology. 58: 813.006. A86.

Rammohan KW, Kangarlu A, Bourekas E, RayChaudhry A. Utility of Ultra high fieldstrength magnetic resonance imaging at 8Tesla in cerebral Cortical Lesions in Multiplr sclerosis - A radiological- Pathological Correlation Study.. Presnted at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA. Neurology. 62 (suppl. 5) : A289. Abstract p04.034. 2004

Sammet, S, Kangarlu, A, Bourekas, E, Rammohan, KW, Koch, RM, and Knopp, MV: MR imaging of a postmortem formalin-fixed human brain of a multiple sclerosis patient at 3T and 7T. ARRS 2007 Annual Meeting. Orlando, FL, 2007.

Sammet, S, Kangarlu, A, Bourekas, E, Rammohan, KW, Koch, RM, and Knopp, MV: MR-Bildgebung eines post mortem formalin-fixierten Gehirns eines Patienten mit multipler Sklerose bei 3T und 7T. 88th Annual DRG Meeting. Berlin, Germany, 2007.
Sammet, S, Kangarlu, A, Bourekas, E, Rammohan, KW, Kooh, RM, and Knopp, MV: MR Imaging of a Postmortem Formalin-Fixed Human Brain of a Multiple Sclerosis Patient at 3T and 7T. ISMRM 2007 Annual Meeting. Berlin, Germany, 2007.

Coyle, PK., Barkof F., Chang P., Jeffery DR., Mikol DO., Stubinski B., Schwid S., Uitdehaag BMJ. On behalf of the REGARD study group. P 2328. The REGARD trial: safety and immunogenecity from a randomized, assessor blinded trial of interferon beta 1a and glatiramer acetate in relapsing remitting multiple sclerosis. Presented at the 23rd Congress of European Committees of Treatment and Research in Multiple Sclerosis. Prague, Czech Republic. Multiple Sclerosis: Volume 13. Supplement 2. October 2007

Mikol, DD., Barkof F., Chang P., Coyle PK., Jeffery DR., Musch S., Schwid S., Uitdehaag BMJ. On behalf of the REGARD study group The REGARD trial: a randomized assessor-blinded trial comparing interferon beta 1a and glatiramer acetate in relapsing-remitting multiple sclerosis. . S 119. Presented at the 23rd Congress of EuropeanCommittees of Treatment and Research in Multiple Sclerosis, Prague, CzechRepublic. Multiple Sclerosis: Volume 13. Supplement 2. October 2007

Kirzinger S, Amason B., Bigley G., Coyle PK., Goodin D., Hurwitz B., Jeffery DR., Lynch S., Mandler, R., Mikol D., Rammohan K., Sater R., Sriram S., Thrower B., et al. On behalf of the

BEYOND ProgrammeFirst phase of the BEYOND Programme: Analysis of 3 year data from an open label extension study comparing 500 mcg and 250 mcg interferon bata1 b. . P181. Presented at the 23rd Congress of European Committees of Treatment and Research in Multiple Sclerosis. Prague, CzechRepublic. Multiple Sclerosis: Volume 13. Supplement 2. October 2007

Barry G.W.Arnason, BEYOND study group.BEYOND - Betaseron efficacy yielding outcomes of a new dose P06.086. Presented at the 56th annual meeting of the American Academy of Neurology. Neurology 62: Number 7; Supplement 5. 2007

Jerry S. Wolinsky et al. and the PROMiSe study group.b Effect of glatiramer acetate on primary progressive multiple sclerosis: Initial analysis of the complete PROMiSe trial. S12.001. Presented at the 56th annual meeting of the American Academy of Neurology. Neurology 62: Number 7; Supplement 5. 2007

R. Philip Kinkel Et.al for the CHAMPIONS study group. Interferon beta 1a (Avonex) delayes the onset of clinically definite MS over 5 years of treatment: results of the CHAMPIONS study. S29.006. Presented at the 56th annual meeting of the American Academy of Neurology. Neurology 62: Number 7; Supplement 5. 2007

Stuart Cook, Patrick Vermersch, Giancarlo Comi, Gavin Giovannoni, Kotti/ Rammohan, Peter Rieckmann, Per Soe/berg-Sorensen, Peter Chang, Anthony Ham/ett, Bruno Musch and Steven Greenberg. Safety and tolerability of c1adribine tablets in relapsing-remitting multiple sclerosis . Consortium of MS Center Annual Meeting, Atlanta, GA, 2009

Peter Rieckmann, Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg-S0rensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch and Steven Greenber g. The CLARITY study: efficacy of c1adribine tablets for relapsing-remitting multiple sclerosis" Consortium of MS Center Annual Meeting, Atlanta, GA, 2009

Gavin Giovannoni, Giancar/o Comi, Stuart Cook, Kotti! Rammohan, Per SoelbergSorensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Peter Rieckmann, Steven Greenberg. Study design of the 96-week, Phase Illb CLARITY extension study. Consortium of MS Center Annual Meeting, Atlanta, GA, 2009

Stuart Cook, Patrick Vermersch, Giancarlo Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-S0rensen, Peter Chang, Anthony Hamlett, Bruno Musch, Vissia Viglietta, Steven Greenberg, on behalf of the CLARITY Study Group. Safety of cladribine tablets in the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS): results from the CLARITY study, a phase III, double-blind, placebo-controlled trial. The 19th Annual Meeting of the European Neurological Society, Milan, Italy. June 2009

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch, Steven

Greenberg. Cladribine Tablets in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS): Efficacy and Safety Results from the CARITY Study – a Phase III, Double-Blind, Placebo-Controlled Study of an Oral Disease-Modifying Drug. Neurology. 2009;73(supp 4):330

Peter Rieckmann, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch and Steven Greenberg. The CLARITY study: Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis.Int J MS Care. 2009;II(Supplement):5.

Peter Riekmann, Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven Greenberg. Study design of the 96-week, phase IIIb CLARITY extension study. Int J MS Care. 2009;II(supplement 2):84.

Stuart Cook, Patrick Vermersch; Giancarlo Comi; Gavin Giovannoni, Kottil Rammohan; Peter Rieckmann, Per Soelberg-Sorensen; Peter Chang; Anthony Hamlett; Bruno Musch; Vissia Viglietta; Steven Greenberg. The CLARITY study: 96-week safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis. Int J MS Care. 2009;II(Supplement 2):64.

Gavin Giovannoni, Giancarlo Comi , Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Solberg-Sorensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Steven GREENBERG. Clinical efficacy of cladribine tablet therapy in patients with Relapsing–Remitting Multiple Sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial. J Neurol 2009; 256 (Suppl 2): S9-S10

Giancarlo Com, Stuart Cook; Gavin Giavannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Steven Greenberg. Magnetic resonance imaging (MRI) outcomes in patients with Relapsing–Remitting Multiple Sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial. J Neurol 2009; 256 (Suppl 2): S49-S50

Per Soelberg-Sørensen, Giancarlo Comi, Stuart Cook, Gavin Giavannoni, Kottil Rammohan, Peter Rieckmann, Patrick Vermersch, Peter Chang, Anthony Hamlett, Vissia Viglietta, Steven Greenberg. Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, Phase III, double-blind, placebo-controlled trial. J Neurol 2009; 256 (Suppl 2): S127-S128.

Stuart Cook, Giancarlo Comi, Gavin Giavannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sorensen, Peter Chang; Anthony Hamlett, Bruno Musch, Rehan Verjee; Steven Greenberg. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. J Neurol 2009; 256 (Suppl 2): S128.

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Steven Greenberg. P470. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo controlled CLARITY study in patients with relapsing-remitting multiple sclerosis . Multiple Sclerosis 2009; Vol 15 (Suppl 2): S136-S137

Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Vissia Viglietta, Steven Greenberg. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo controlled CLARITY study in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis 2009; Vol 15 (Suppl 2): S136

Patrick Vermersch, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Peter Chang, Anthony Hamlett, Bruno Musch, Rehan Verjee, Steven Greenberg. Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Multiple Sclerosis 2009; Vol 15 (Suppl 2): S249

Kottil Rammohan, Patrick Vermersch, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg-Sørensen, Peter Chang, Anthony Hamlett, Bruno Musch, Rehan Verjee, Steven Greenberg. Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Multiple Sclerosis 2009; Vol 15 (Suppl 2)

Per Soelberg-Sørensen, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Patrick Vermersch, Peter Chang, Anthony Hamlett, Vissia Viglietta, Rehan Verjee, Bruno Musch, Steven Greenberg. Multiple Sclerosis 2009; Vol 15 (Suppl 2): S137.

Peter Rieckmann, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Vissia Viglietta, Bruno Musch, Steven Greenberg. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Multiple Sclerosis 2009; Vol 15 (Suppl 2): S248-S249.

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Rehan Verjee, Téa Fevr, Vissia Viglietta, Steven Greenberg. P471. Multiple Sclerosis 2009; Vol 15 (Suppl 2): S137.

Stuart Cook, Patrick Vermersch, Giancarlo Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Peter Chang, Anthony Hamlett, Bruno Musch, Vissia Viglietta, Steven Greenberg. Safety and tolerability of cladribine tablets in relapsing-remitting

multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Multiple Sclerosis 2009; Vol 15 (Suppl2): S20.

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven Greenberg. Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1):

Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Vissia Viglietta, Steven Greenberg. MRI outcomes of short-course oral treatment with cladribine tablets for relapsing–remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1)

Stuart Cook, Patrick Vermersch, Giancarlo Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Peter Chang, Anthony Hamlett, Bruno Musch, Vissia Viglietta, Steven Greenberg. Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1): S206

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven Greenberg. Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1): S114.

Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang, Anthony Hamlett, Bruno Musch, Téa Fevr, Vissia Viglietta, Steven Greenberg. MRI outcomes of short-course oral treatment with cladribine tablets for relapsing–remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1)

Stuart Cook, Patrick Vermersch, Giancarlo Comi, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Peter Chang, Anthony Hamlett, Bruno Musch, Vissia Viglietta, Steven Greenberg. Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. J Neurol Sci 2009; 285 (Suppl.1): S206.

Gavin Giovannoni , Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang, Anthony Hamlett, Rehan Verjee, Bruno Musch, Steven Greenberg. Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets,

in the Double-Blind, 96-Week CLARITY Study. For presentation at the Annual meeting of the AAN , Toronto 2010.

Per Soelberg-Sørensen , Peter Rieckmann, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Patrick Vermersch, Anthony Hamlett, Tea Fevr, Bruno Musch, Steven Greenberg. Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing–Remitting Multiple Sclerosis (RRMS). For presentation at the Annual meeting of the AAN , Toronto 2010.

Kottil Rammohan, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg-Sørensen, Patrick Vermersch; Peter Chang, Anthony Hamlett, Rehan Verjee, Bruno Musch, Steven Greenberg. Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study. For presentation at the Annual meeting of the AAN , Toronto 2010.

Shehzad Ali, Stuart Cook, Gavin Giovannoni, Giancarlo Comi, Steven Greenberg, Alexandre Joyeux, Kottil Rammohan, Noman Paracha, Peter Rieckmann, Per Soelberg Sorensen, Patrick Vermersch, Bruno Musch. Health Resource Utilization in the CLARITY Study. For presentation at the Annual meeting of the AAN , Toronto 2010.

TEACHING

Teaching Award
Faculty Inductee and Annual Key note Speaker: 1999
Alpha Omega Alpha
Ohio State University, Class of 1999

Professor of the Year 2001
Department of Neurology
Ohio State University

Outstanding Teacher of the Year 2004
Department of Neurology
Ohio State University

Professor of the Year 2006
Department of Neurology
Ohio State University

SERVICE

Awards and Honors - Community Services
The Hope Award 1989
For outstanding and long-term services to the National Multiple Sclerosis Society.

The Spirit Award 2002
For Loyal Support of the MS cause. Awarded by the National MS Society, Ohio Buckeye Chapter

Outstanding ***Physician Recognition Award*** 2002
For out-standing care of MS patients in the community. Recognized by the National MS Society, Ohio Buckeye Chapter

Inducted into the ***National MS Hall of Fame*** 2003
Peer recognition for outstanding service for the MS cause at a national level. Awarded by the National MS Society.

Best Doctors in America. Multiple years, including most recently 2009.

Service Award
The Dwight Palmer Award
Outstanding Dedication and Service,
Department of Neurology